"The voice for cancer physicians and their patients in Massachusetts."

FDA Approves Brentuximab vedotin (Adcetris) for the Adult Patients with pc-ALCL

16 Nov 2017 11:00 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration granted regular approval to brentuximab vedotin (Adcetris; Seattle Genomics) for the treatment of adult-patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systematic therapy. Read full press release. 

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software